At Johnson & Johnson, our ambition is to help eliminate prostate cancer. Through collaboration with patients, caregivers, and healthcare professionals – including leading specialists – we are driven to make our ambition a reality. With over 30 years of innovation in oncology, we are working to get in front of prostate cancer by harnessing the power of precision medicine and developing the next wave of therapeutics.
Our prostate cancer platform provides up-to-date resources, tools and expert insights to support informed decision-making.


Join our upcoming symposia and webinars hosted by our leading specialists. Register for events and access to post event recordings and materials available exclusively for J&J Medical Cloud users.
12-16 September 2026
Stockholm, Sweden
We're excited to host a GU medical education industry satellite symposium at ECP 2026. Join us in Stockholm for engaging discussions and expert insights in GU oncology.
Madrid, Spain
5-8 November 2026
Brussels, Belgium
We look forward to EMUC 2026, where we will deliver a dedicated prostate cancer medical education symposium, with insights and full programme details coming soon
Register or sign in for J&J Medical Cloud to unlock access to upcoming events, stay updated on the latest educational opportunities, and connect with a network of healthcare professionals.Â
Explore the latest educational content on our website, featuring expert-led sessions, insights from KOLs, and practical tools designed to support your continuous learning and enhance your clinical practice.
Two dynamic sessions featuring a Prostate Cancer Symposium focused on evolving standards of care through multidisciplinary, case-based discussion, and a Diversity in GU Workshop sharing global insights and practical strategies to advance diversity in GU medicine.
The power of precision medicine: Transforming patient outcomes in GU oncology
An expert panel – including Dr. Elena Castro, Prof. Dr. Axel Heidenreich, and Dr. Alejo RodrÃguez-Vida – examine key clinical considerations in GU cancer care.
Our prostate cancer session – ‘Driving optimal patient outcomes with personalised strategies in mHSPC’ – examines how PSA response guides optimal care in mHSPC and highlights strategies to improve outcomes in HRR-mutant disease.
Our annual meeting - for those earlier in their career specialisation in prostate cancer, focuses on networking, interactive scientific discussions, and enhancing specific skills to improve patient care across the EMEA region by best practice sharing.
A patient-centric platform designed to support patients throughout their healthcare journey. It provides personalised, high-quality content and services to enhance patient engagement.
By empowering informed, proactive patients, J&J withMe helps improve treatment outcomes.
Learn how this platform can strengthen your patient relationships: explore J&J withMe today!
Johnson & Johnson - A proud Gold Sponsor of APCCC 2026 - a great opportunity for physicians to connect with leading experts from around the world.
Discover educational content designed to enhance your daily practice. Our Learning Centre is dedicated to addressing the evolving needs of healthcare professionals and fostering the diverse skill set essential for delivering high-quality care.

Stay informed with our Event Centre – your hub for medical education events, expert faculty interviews, and clinical insights. Browse on-demand content from past events and hear from leaders shaping patient care.
Gain valuable insights from leading experts in the field as they share their knowledge on key topics and provide informed answers to common questions. Stay informed and enhance your understanding with expert perspectives!

Prof. Gero Kramer and Dr. Ercan Müldür discuss new developments in mHSPC and the evolving role of triple therapy approaches for patients with HRR/BRCA alterations.
Held in German with subtitles, accessible for all to view, learn and localise.

Dr. Elena Castro, Dr. Pasquale Rescigno, Prof. Gert Attard and Prof. Axel Heidenreich discuss how personalised approaches, genomic testing, and targeted therapies are transforming prostate cancer care and improving patient outcomes.

Prof. Eleni Efstathiou, Prof. Gert Attard, Dr. Elena Castro, and Dr. Brigida Maiorano examine the latest trials and discuss the need for earlier testing in mPC to aid treatment decisions.
Note: To access more expert insights, you can register or sign in to J&J Medical Cloud. Stay informed about the latest educational resources and updates from Johnson & Johnson Innovative Medicine by signing up for our communications.
Our scientists and researchers are pioneering the path from lab to life and championing patients each step of the way.
Our educational programs are developed and reviewed in partnership with a global network of healthcare leaders.
We work with medical societies to support joint initiatives that enhance healthcare outcomes and foster professional education.
Supporting healthcare professionals to engage in ongoing discussions about the latest scientific advancements.
We value your connection. Sign up to stay informed about the latest educational resources, and updates. By subscribing, you'll receive timely notifications and exclusive content tailored to your interests.
To report an Adverse Event (medication side-effect) or a Product Quality Complaint (an issue with one of our products), please select the appropriate link from the Contact dropdown menu. To submit a medical information request, choose the Medical Information page.
BRCA, breast cancer gene; GU, genitourinary; HRR, homologous recombinant repair; mHSPC, metastatic hormone-sensitive prostate cancer; PSA, prostate-specific antigen.























